SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as community members rally around the self-proclaimed "first ETF on Solana," with many highlighting the strong community and encouraging others to "load up" for a potential "meme season." Despite some skepticism, supporters express confidence in the project's long-term potential and encourage holding through market fluctuations. The project's branding and community-driven nature appear to be key talking points.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to positive case studies highlighting the effectiveness of its CyPath Lung test for early lung cancer detection, potentially reducing unnecessary biopsies. The stock's low float and recent reverse split are fueling community discussions about a potential squeeze, with some anticipating a run to higher price levels. Bullish sentiment revolves around the company's cancer detection technology and its potential for a large market opportunity.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses a mix of factors, including analyst upgrades citing AI and robotaxi potential, and debates over valuation. Some traders point to technical signals and anticipate further upward movement, while others express concerns about sales figures and potential pullbacks. Additionally, discussions around Elon Musk's involvement in the Epstein files are circulating.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors assess its future growth potential amid discussions around government funding and domestic rare earth production. Community members are weighing the impact of strategic partnerships and production gains, while also debating potential connections to political figures. Some traders are closely watching technical indicators and options activity for potential entry points, while others express concerns about short-term volatility.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts is trending amid reports of a potential leveraged buyout valued at $50 billion, backed by investors like Silver Lake and Saudi Arabia's Public Investment Fund, leading to a surge in stock price and trading halts. The community is discussing the potential buyout price and impact on other video game stocks, while also reflecting on the company's past performance and future prospects. Some investors express concerns about debt, the quality of games, and the implications for the gaming sector as a whole.

BTQ Technologies Corp

BTQ is trending as investors discuss the potential impact of a $300 million registration for dilution after its NASDAQ debut, with some expressing disappointment and others viewing it as a long-term buying opportunity. Community members are debating the company's valuation and revenue prospects in the quantum cybersecurity space, while awaiting news about Robinhood availability. Some investors remain bullish, citing a deal with Danal and the potential for BTQ to become a leader in quantum-safe technology.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members speculate about potential partnerships with Apple and TSMC and how this might impact the company's growth and stock value. Traders are actively discussing potential price movements, with many eyeing the $40 mark, and attributing the stock's momentum to government support for domestic chip manufacturing. Some investors believe that Intel is undervalued compared to its peers, while others suggest caution, pointing to technical indicators and potential overbought conditions.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as the community focuses on its potential within the DEX and DeFi space, particularly its trending status and potential price movements. Bullish sentiment seems to be fueled by discussions around breaking resistance levels and predictions of continued upward momentum. Some traders are drawing comparisons to similar projects and anticipating substantial growth, while others urge caution and highlight the inherent volatility.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals ($CRNX) is trending as the community discusses its potential, driven by the recent FDA approval of Palsonify for acromegaly. Community members are actively discussing the steady share price post-approval and anticipating a second leg up, with some suggesting the stock could reach triple digits in the coming year. Bullish sentiment is fueled by the drug's clean label, expansion into Europe, and convenience for patients, while others point to high institutional ownership and potential for a short squeeze.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

AQMS is trending due to recent momentum and speculative interest in low-float stocks, particularly within the lithium sector. The community is actively discussing the stock's potential for a significant breakout and potential short squeeze, drawing comparisons to other high-flying stocks in the sector. Aqua Metals' participation in an upcoming battery show and a focus on critical minerals may be contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study

uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

U.S.-listed shares of UniQure surged to a five-year high and posted&nbsp;their best session ever after analysts raised price targets following three-year data from its Huntington’s gene therapy AMT-130.&nbsp;The stock closed Wednesday up 247.7% at $47.50, and added another 5.8% gain in after-hours trading.On Wednesday,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">UniQure announced</a> that patients&nbsp;receiving a high dose of its gene therapy, AMT-130,&nbsp;experienced a 75% reduction in Huntington’s disease progression over three years, based on a key clinical scale (cUHDRS), and a 60% reduction in daily function (TFC). The company added that the treatment was generally well-tolerated, with no new serious side effects linked to the drug.Stifel raised its price target on&nbsp;QURE to $65 from $30 and&nbsp;maintained a ‘Buy’&nbsp;rating, citing a larger market opportunity, higher approval probability, and alignment with the FDA.&nbsp;H.C. Wainwright reiterated a ‘Buy’ with a $70 target, highlighting statistically significant and dose-dependent slowing of disease progression, substantial slowing of neurological decline, and supporting a BLA (Biologics License Applications) filing in the first quarter (Q1) of 2026 with potential accelerated approval.Leerink noted that the pivotal Phase 1/2 study met its primary endpoint and several&nbsp;secondary endpoints, stating that the data support approval with minimal regulatory flexibility needed. It also raised its target to $68 from $48 with an ‘Outperform,’ calling the results a “game-changer” and “definitive win.”Citi called the data “very compelling” and a “high bar” for Huntington’s. RBC Capital raised UniQure’s target to $55 from $24 with an ‘Outperform,’ saying the company “likely has a drug for a devastating disease that comes with 12x higher risk of committing suicide.”Separately, UniQure commenced a $200 million underwritten public offering of ordinary shares and pre-funded warrants. Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities are acting as bookrunning managers.On Stocktwits, retail sentiment for UniQure was ‘extremely bullish’ amid ‘extremely high’ message volume, placing it among the platform’s top 10 trending equities.One user noted that,&nbsp;despite being a long-time bull, they did not expect the stock to climb after the offering and suggested that the deal may have been smaller than anticipated.&nbsp;<stembedurl>https://stocktwits.com/ApproxModDur/message/629892988</stembedurl>Another described UniQure as a “diamond in the rough of biotech,” adding that they believed the shares could rise fivefold over the long term regardless of short-term price swings.<stembedurl>https://stocktwits.com/jaj89/message/629888795</stembedurl><a href="https://stocktwits.com/symbol/QURE">UniQure’s U.S.-listed stock</a> has risen 169% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’

UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.

Equity

U.S. equities declined in Wednesday’s afternoon trade as investors cautiously await the release of key economic data this week, including the third estimate of gross domestic product (GDP) for the second quarter (Q2) on Thursday, and the personal consumption expenditures (PCE) price index on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.39% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.6%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.31%.Here are the top stocks making the biggest moves in Wednesday’s midday trade:<a href="https://stocktwits.com/symbol/LAC">Lithium Americas Corp. (LAC)</a>Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lithium-americas-stock-surge-captures-wall-street-attention-here-is-why/chD1GtUR33g">confirmed</a> that it is in talks with the U.S. Department of Energy and its joint venture partner General Motors Co. (GM) in the Thacker Pass lithium project over the renegotiation of a $2.26 billion Energy Department loan.<a href="https://stocktwits.com/symbol/LAC">LAC stock</a> is up 101% year-to-date.<a href="https://stocktwits.com/symbol/BABA">Alibaba Group Holdings (BABA)</a>Alibaba’s U.S.-listed shares surged more than 9% in Wednesday’s afternoon session after the company announced plans to boost investment in artificial intelligence by over $53 billion.<a href="https://stocktwits.com/symbol/BABA">BABA stock</a> is up 110% year-to-date.<a href="https://stocktwits.com/symbol/QURE">uniQure NV (QURE)</a>uniQure shares soared more than 260% on Wednesday afternoon after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">said</a> that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is up 178% year-to-date.<a href="https://stocktwits.com/symbol/IREN">IREN (IREN)</a>IREN shares surged over 16% on Wednesday afternoon following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iren-stock-surged-15-percent-today-here-is-a-price-target-update/chD1drjR33t">announcement</a> by the company that it has doubled its AI Cloud capacity to a total of 23,000 GPUs (graphic processing units), supporting the company’s goal of achieving more than $500 million in annualized AI Cloud revenue by the first quarter of 2026.<a href="https://stocktwits.com/symbol/IREN">IREN stock</a> is up 393% year-to-date.<a href="https://stocktwits.com/symbol/CDTX">Cidara Therapeutics Inc. (CDTX)</a>Cidara shares gained over 21% in Wednesday’s afternoon trade after the company announced plans for a Phase 3 study for CD388, a non-vaccine preventative of seasonal influenza.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up 232% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/scott-bessent-surprised-by-strength-of-fed-chair-candidates/chD1cDJR33N">Scott Bessent Says He’s Surprised By Strength Of Fed Chair Candidates: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today

Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the firm confirmed that it is in talks with the Energy Department and GM over the $2.6 billion Thacker Pass project loan.

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Shares of the company rose a whopping 161% in the pre-market session at the time of writing.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">stated</a> that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease. The company also identified a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) at 36 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.uniQure on Wednesday said that the therapy was generally well-tolerated in the trial with a manageable safety profile. No new drug-related serious adverse events have been observed from December 2022 to the end of June 2025, it added.Chief Medical Officer Walid Abi-Saab said that the company is looking forward to discussing the data with the U.S. Food and Drug Administration at a meeting later this year. The company plans to submit an application for approval of AMT-130 to the FDA in the first quarter of 2026 and anticipates launching it in the U.S. later in the same year.According to the company, there are currently no approved therapies to slow the progression of Huntington’s disease. The disease affects approximately 75,000 people in the U.S., EU, and the U.K., it added.QURE stock is down by 23% this year but has risen approximately 166% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

Shares of uniQure N.V. (QURE) were in the spotlight on Friday morning after its first quarter (Q1) revenue fell 81% year-on-year (YoY) while losses narrowed.The gene therapy company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/09/3078125/0/en/uniQure-Announces-First-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html">reported</a> revenue for the three months ended March of $1.6 million, compared to $8.5 million in the same period of 2024, and below an analyst estimate of $6.71 million, as per Finchat data.The company attributed the revenue fall to a decrease of $4 million in contract manufacturing of HEMGENIX gene therapy for biotherapeutics company CSL Behring, among other factors.uniQure, however, narrowed its quarterly loss to $0.82 per share, compared to a loss of $1.36 in the corresponding period of 2024. Analysts were estimating a loss of $1.06 per share.The narrowing of the net loss in the quarter was driven by a significant reduction in the company’s operating expenses, as it slashed employee-related expenses, facility expenses, and costs related to preclinical supplies.The firm ended the quarter with cash, cash equivalents, and current investment securities of approximately $409 million, expected to fund its operations into the second half of 2027.The company is now seeking U.S. FDA approval for its AMT-130 gene therapy as a treatment for Huntington’s disease.CEO Matt Kapusta said that the company expects to provide a regulatory update on AMT-130 in the second quarter, including guidance on the potential timing for its application to the FDA seeking approval to distribute the therapy.On Stocktwits, retail sentiment around uniQure remained unmoved within the ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_8_08_00_AM_png_281dbf2952.webp" alt="QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE/sentiment">QURE stock</a> declined by 32% this year but is up by about 142% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-reports-positive-data-from-cancer-drug-trial/chiWpd3RblJ">AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

QURE
uniQure NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest QURE News

QURE uniQure NV